TICKERNERD
Menu
ALMRHealthcare · Medical Devices

ALMR Stock Forecast: Alamar Biosciences, Inc. (California) Price Predictions for 2026-2027

Last close, 24 Aug 2026
$33
−4.50% on the day

The 5 Wall Street analysts covering Alamar Biosciences, Inc. (California) hold a median 12-month price target of $34 — +4.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap
$2.4B
Ticker Nerd rank
4 / 100
Median analyst target
$34
Analysts covering
5
Total return, dividends reinvested
1W
+1.8%
1M
+26.4%
From high
−10.6%
From low
+71.3%
$19
$37
Range since 17 Apr 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

ALMR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alamar Biosciences, Inc. (California) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
4 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
82
Size
34
Momentum
15
Value
10
Growth
8
Accruals
8
Quality
4
Issuance
3
Volatility
3

Revisions (82): Analysts have, on balance, been raising their forecasts.

Volatility (3): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALMR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALMR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 17 Apr 2026Adjusted close, US dollars
$20$25$30$35May 26Jun 26Jul 26Aug 26ALMRHigh $35Median $34Low $31

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $31Median $34High $35

The green dot is the last close — the median target sits +4.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026JP MorganMaintainsOverweight$32 → $35
11 Aug 2026StifelMaintainsBuy$28 → $32
12 May 2026JP MorganInitiatesOverweight—
12 May 2026JP MorganInitiatesOverweight$30
12 May 2026Leerink PartnersInitiatesOutperform—
12 May 2026Leerink PartnersInitiatesOutperform$35
12 May 2026StifelInitiatesBuy—
12 May 2026StifelInitiatesBuy$28
12 May 2026TD CowenInitiatesBuy—
12 May 2026TD CowenInitiatesBuy$30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALMR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ALMR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

ALMR vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160May 26Jun 26Jul 26Aug 26ALMRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALMR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Alamar Biosciences, Inc. (California) (ALMR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−76.4×

Cheaper than 99% of US stocks

Price / sales
23.7×

Cheaper than 9% of US stocks

Price / book
7.6×

Cheaper than 14% of US stocks

EV / EBITDA
−58.1×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
82.1%

Higher than 91% of US stocks

Earnings growth (YoY)
—
Gross margin
55.5%

Higher than 69% of US stocks

Operating margin
−46.0%

Higher than 17% of US stocks

Net margin
−49.5%

Higher than 10% of US stocks

Returns & dividend
Return on equity
18.8%

Higher than 80% of US stocks

Return on assets
−21.3%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Alamar Biosciences, Inc. (California) (ALMR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alamar Biosciences, Inc. (California) has a market value of $2.4B and an enterprise value of $2.2B.

  • Shares outstanding: 66.5M.

  • Trailing P/E: −76.4×; forward P/E: −63.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Alamar Biosciences, Inc. (California) employs 286 people.

market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

ALMR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ALMRAlamar Biosciences, Inc. (California)$2.4B
4
UFPTUFP Technologies, Inc.$2.4B
74
BFLYButterfly Network, Inc.$2.6B
72
NEOGNeogen Corp.$2.6B
96
ESTAEstablishment Labs Holdings, Inc.$2.1B
76
AXGNAxoGen, Inc.$2.7B
77
NVCRNovoCure Ltd.$2.0B
96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alamar Biosciences, Inc. (California) — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALMR news & analysis

Alamar Biosciences: Promising But Expensive Proteomics Growth

Seeking Alpha · 16 Aug 2026neutral

A Seeking Alpha article discusses Alamar Biosciences' ARGO instruments, which automate NULISA assays and could convert instrument placements into recurring demand for consumables. The article notes consumables are growing faster than instruments, but questions whether this will be long-term profitable growth as the installed base expands.

Why it matters — ALMR watchers would care because the shift from instrument placements to recurring consumables revenue is central to the company's growth model, and the article raises questions about the long-term profitability of that expansion.

Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument

Seeking Alpha · 14 Aug 2026positive

Alamar Biosciences reported Q2 2026 revenue of $29.4M, up 82% year-over-year, with consumables sales up 147% and gross margin rising to 60%. The article highlights the company's content-driven proteomics platform, expanding biomarker panels, installed base, and recurring revenue opportunities as drivers of long-term growth.

Why it matters — ALMR watchers would care because the item highlights accelerating consumables revenue, improving gross margins, and recurring revenue potential from its installed base, which are key indicators of the company's growth trajectory and revenue quality.

Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum

Benzinga · 11 Aug 2026positive

Alamar Biosciences shares are trading higher after the company announced it is expanding its global partnership with the Alzheimer's Disease Data Initiative and Gates Ventures. CEO comments that the company is well-positioned to sustain its upcoming momentum.

Why it matters — Alamar Biosciences watchers would care because the expanded partnership with major Alzheimer's-focused organizations signals strengthened strategic collaborations that could support the company's future trajectory.

Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Call Transcript

Seeking Alpha · 10 Aug 2026neutral

Alamar Biosciences, Inc. (ALMR) held its Q2 2026 earnings call, and a transcript of the call was published on Seeking Alpha. The item reports the availability of the earnings call transcript.

Why it matters — ALMR watchers would want to review the transcript to hear management's discussion of the company's Q2 2026 performance and outlook directly from its executives.

Alamar Biosciences Q2 Earnings Call Highlights

MarketBeat · 10 Aug 2026positive

Alamar Biosciences reported second-quarter 2026 revenue of $29.4 million, an 82% increase year over year, driven by growth in consumables, instrument placements and service revenue. The earnings call was the company's first since completing its April initial public offering.

Why it matters — The strong revenue growth and first post-IPO earnings call provide an early look at Alamar's financial trajectory as a newly public company.

FAQ

Frequently asked questions about ALMR stock

What is the ALMR stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Alamar Biosciences, Inc. (California) have a median 12-month price target of $34, with estimates ranging from $31 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALMR stock a buy right now?

Of the 5 analysts covering Alamar Biosciences, Inc. (California), 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alamar Biosciences, Inc. (California) 4 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALMR?

As at 22 Aug 2026, Alamar Biosciences, Inc. (California) ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (82 of 100).

Will ALMR stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +4.0% from the last close, and Ticker Nerd's factor model ranks Alamar Biosciences, Inc. (California) 4 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALMR stock forecast for 2030?

No analyst covering Alamar Biosciences, Inc. (California) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALMR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $31 to $35 over the next 12 months.

What does Alamar Biosciences, Inc. (California) do?

Alamar Biosciences, Inc. is a commercial-stage proteomics company specializing in advanced protein detection and analysis technologies.

What is the latest news on ALMR?

The most recent item we track (Seeking Alpha, 16 Aug 2026): "Alamar Biosciences: Promising But Expensive Proteomics Growth". A Seeking Alpha article discusses Alamar Biosciences' ARGO instruments, which automate NULISA assays and could convert instrument placements into recurring demand for consumables. The article notes consumables are growing faster than instruments, but questions whether this will be long-term profitable growth as the installed base expands.

Company

About Alamar Biosciences, Inc. (California).

Alamar Biosciences, Inc. is a commercial-stage proteomics company specializing in advanced protein detection and analysis technologies. It develops and commercializes the proprietary NULISA platform, designed to overcome limitations of traditional proteomics tools by enabling detection of protein biomarkers at extremely low concentrations in non-invasive biological fluids like blood. Key features include ultra-high sensitivity, high specificity, flexible multiplexing capabilities, broad dynamic range, and seamless automation, establishing a gold standard for precision proteomics. The company serves the healthcare sector, particularly the medical devices industry, by providing tools for disease detection research, including early identification of cancer and other diseases through protein biomarker platforms. Alamar Biosciences, Inc. focuses on powering precision medicine applications in research and diagnostics. Founded in 2018 and headquartered in Fremont, California, it plays a significant role in advancing proteomics for biological and clinical research.

CEO Dr. Yuling Luo Ph.D. · 286 employees · United States · https://alamarbio.com